Federal Register / Vol. 65, No. 97 / Thursday, May 18, 2000 / Notices 31583

Agenda: Administrative Reports and

Program Development

Place: National Library of Medicine, Board

Room Bldg 38, 2E–09, 8600 Rockville Pike,

Bethesda, MD 20894

Closed: June 15, 2000, 9 am to 12 pm

Agenda: To review and evaluate grant

applications

Place: National Library of Medicine, Board

Room Bldg 38, 2E–09, 8600 Rockville Pike,

Bethesda, MD 20894

Closed: June 15, 2000, 12 pm to 1:30 pm

Agenda: To review and evaluate resource

grant applications

Place: National Library of Medicine, Board

Room Bldg 38, 2E–09, 8600 Rockville Pike,

Bethesda, MD 20894

Contact Person: Sharee Pepper, Phd,

Scientific Review Administrator, Health

Scientist Administrator, Office of Extramural

Programs, National Library of Medicine, 6705

Rockledge Drive Suite 301, Bethesda, MD

20892, (301) 594–4933

(Catalogue of Federal Domestic Assistance

Program Nos. 93.879, Medical Library

Assistance, National Institutes of Health,

HHS)

Dated: May 10, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–12540 Filed 5–17–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of

Closed Meetings

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meetings.

The meetings will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: Center for Scientific

Review Special Emphasis Panel.

Date: May 30, 2000.

Time: 10 am to 1 pm.

Agenda: To review and evaluate grant

applications.

Place: NIH, Rockledge 2, Bethesda, MD

20892 (Telephone Conference Call).

Contact Person: Dharam S. Dhindsa, DVM,

Phd, Scientific Review Administrator, Center

for Scientific Review, National Institutes of

Health, 6701 Rockledge Drive, Room 5126,

MSC 7854, Bethesda, MD 20892, (301) 435–

1174, dhindsad@csr.nih.gov.

Name of Committee: Center for Scientific

Review Special Emphasis Panel.

Date: May 30–31, 2000.

Time: 6 pm to 5 pm.

Agenda: To review and evaluate grant

applications.

Place: American Inn of Bethesda, 8130

Wisconsin Ave, Bethesda, MD 20814.

Contact Person: Ramesh K. Nayak, Phd,

Scientific Review Administrator, Center for

Scientific Review, National Institutes of

Health, 6701 Rockledge Drive, Room 5146,

MSC 7840, Bethesda, MD 20892, (301) 435–

1026.

Name of Committee: Center for Scientific

Review Special Emphasis Panel.

Date: May 31–June 1, 2000.

Time: 8:30 pm to 5 pm.

Agenda: To review and evaluate grant

applications.

Place: Holiday Inn, 5520 Wisconsin Ave,

Palladian West, Chevy Chase, MD 20815.

Contact person: Gamil C. Debbas, PhD,

Scientific Review Adminsitrator, Center for

Scientific Review, National Institutes of

Health, 6701 Rockledge Drive, Room 5170,

MSC 7844, Bethesda, MD 20892, (301) 435–

1018.

Name of Committee: Center for Scientific

Review Special Emphasis Panel.

Date: May 31, 2000.

Time: 1 pm to 4 pm.

Agenda: To review and evaluate grant

applications.

Place: NIH, Rockledge 2, Bethesda, MD

20892 (Telephone Conference Call).

Contact Person: Dharam S. Dhindsa, DVM,

PhD, Scientific Review Administrator, Center

for Scientific Review, National Institutes of

Health, 6701 Rockledge Drive, Room 5126,

MSC 7854, Bethesda, MD 20892, (301) 435–

1174, dhindsad@csr.nih.gov

Name of Committee: Center for Scientific

Review Special Emphasis Panel.

Date: May 31, 2000.

Time: 2 pm to 4 pm.

Agenda:To review and evaluate grant

applications and/or proposals

Place: NIH, Rockledge 2, Bethesda, MD

20892 (Telephone Conference Call).

Contact Person: Syed Amir, PhD, Scientific

Review Administrator, Center for Scientific

Review, National Institutes of Health, 6701

Rockledge Drive, Room 6168, MSC 7892,

Bethesda, MD 20892 (301) 435–1043.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.306, Comparative Medicine,

93.306; 93.333, Clinical Research, 93.333,

93.337, 93.393–93.396, 93.837–93.844,

93.846–93.878, 93.892, 93.893, National

Institutes of Health, HHS)

Dated: May 10, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–12537 Filed 5–17–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: Uridine Prodrug Analogues:

Uses in Cancer Diagnosis and Therapy

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i), that the National

Institutes of Health, Department of

Health and Human Services, is

contemplating the grant of an exclusive

license to practice the inventions

embodied in PCT Patent Application S/

N PCT/US98/23109 (23109) entitled,

‘‘Antitumor Uridine Analogs’’ which

was filed on October 10, 1998 and

claims priority to U.S. Patent

Application S/N 60/063,587 entitled,

‘‘Diagnosis and Treatment of Tumors

with Drugs Activated by Thymidylate

Synthase,’’ which was filed on October

10, 1997 to Nascent Pharmaceuticals

LLC of San Francisco, California. The

patent rights in these inventions have

been assigned to the United States of

America.

The prospective exclusive license

territory will be worldwide and the field

of use may be limited to human

therapeutics and diagnostics for the

detection and treatment of breast and

gastrointestinal cancers.

DATES: Only written comments and/or

license applications which are received

by the National Institutes of Health on

or before July 17, 2000 will be

considered.

ADDRESSES: Requests for copies of the

patent, inquiries, comments and other

materials relating to the contemplated

exclusive license should be directed to:

Richard U. Rodriguez, M.B.A.,

Technology Licensing Specialist, Office

of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville, MD.

20852–3804. Telephone: (301) 496–

7056, X287; Facsimile (301) 402–0220;

E-mail rr154z@nih.gov.

SUPPLEMENTARY INFORMATION: The

technology claimed in ‘23109 relates to

methods, compounds and compositions

for diagnosing and/or treating cancers

with anti-tumor agents activated by

thymidylate synthase (TS) and/or

thymidine kinase (TK). In addition, the

invention relates to the preparation and

use of positron emitting nucleoside

analogues for imaging applications.

TS is an essential enzyme for DNA

synthesis, and it has been shown to be